Uemura et al. reported that ABCC11 directly confers resistance to MTA by enhancing the efflux of intracellular anti-cancer drugs in lung cancer [38], which suggests that ABCC11 may be a biomarker for MTA in the treatment of lung cancer. This evidence concerns the gene ABCC11 and lung carcinoma.